On January 8, 2026, Xilio Therapeutics, Inc. reported that Sara M. Bonstein was appointed as chair of the Board, succeeding Paul Clancy, who retired on January 6, 2026, without any disagreement. Additionally, the company estimates having approximately $137.5 million in cash as of December 31, 2025, based on preliminary data.